Screening for differential methylation status in human placenta in preeclampsia using a CpG island plus promoter microarray

  • Authors:
    • Rui-Zhe Jia
    • Xiang Zhang
    • Ping Hu
    • Xiao-Mei Liu
    • Xiang-Dong Hua
    • Xin Wang
    • Hong-Juan Ding
  • View Affiliations

  • Published online on: April 25, 2012     https://doi.org/10.3892/ijmm.2012.983
  • Pages: 133-141
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The development of preeclampsia (PE) seriously affects the health of the mother and the child, but the precise pathogenesis of PE remains elusive. The placenta is considered to play a key role and DNA methylation may be associated with altered placental development and function. The aim of this study was to perform a genome-wide analysis of the DNA methylation profile in placentas from pregnancies with severe preeclampsia. The authors analyzed normal and placental tissues with PE for aberrant DNA methylation using methylated DNA immunoprecipitation (MeDIP) and a human CpG island plus promoter microarray. The methylation status of identified candidate genes were validated by bisulfite sequencing PCR (BSP). Microarray analysis identified 296 genes that showed significantly aberrant DNA methylation in preeclampsia (PE). These genes were located more frequently in chromosome 1 (10.5%, P=0.005), chromosome 12 (8.1%, P=0.062) and chromosome 19 (7.4%, P=0.117). Functional analysis divided these genes into different functional networks. In addition, the methylation profile of six of these genes (CAPN2, EPHX2, ADORA2B, SOX7, CXCL1 and CDX1) in nine patients with PE was validated by BSP. This study demonstrated aberrant patterns of DNA methylation in PE, which may be involved in the pathophysiology of PE. Future work will assess the potential prognostic and therapeutic value for these findings in PE.

Related Articles

Journal Cover

July 2012
Volume 30 Issue 1

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jia R, Zhang X, Hu P, Liu X, Hua X, Wang X and Ding H: Screening for differential methylation status in human placenta in preeclampsia using a CpG island plus promoter microarray. Int J Mol Med 30: 133-141, 2012.
APA
Jia, R., Zhang, X., Hu, P., Liu, X., Hua, X., Wang, X., & Ding, H. (2012). Screening for differential methylation status in human placenta in preeclampsia using a CpG island plus promoter microarray. International Journal of Molecular Medicine, 30, 133-141. https://doi.org/10.3892/ijmm.2012.983
MLA
Jia, R., Zhang, X., Hu, P., Liu, X., Hua, X., Wang, X., Ding, H."Screening for differential methylation status in human placenta in preeclampsia using a CpG island plus promoter microarray". International Journal of Molecular Medicine 30.1 (2012): 133-141.
Chicago
Jia, R., Zhang, X., Hu, P., Liu, X., Hua, X., Wang, X., Ding, H."Screening for differential methylation status in human placenta in preeclampsia using a CpG island plus promoter microarray". International Journal of Molecular Medicine 30, no. 1 (2012): 133-141. https://doi.org/10.3892/ijmm.2012.983